NCT05518799View on ClinicalTrials.gov

CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Prostate CancerSolid Tumor, Adult
Interventions
DRUG

Midazolam

Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.

Trial Locations (1)

1066CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT05518799 - CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours | Biotech Hunter | Biotech Hunter